期刊文献+

PD-1、PD-L1蛋白在外周T细胞淋巴瘤中的表达及其与预后的关系 被引量:7

The PD-1 and PD-L1 Protein Expression in Peripheral T cell Lymphoma and Their Correlation with Prognosis
下载PDF
导出
摘要 目的探讨外周T细胞淋巴瘤(peripheral T cell lymphoma,PTCL)患者肿瘤组织中程序性细胞死亡受体1(programmed cell death-1,PD-1)和程序性细胞死亡受体1配体(programmed death ligand 1,PD-L1)蛋白的表达情况,分析其与患者预后的关系。方法采用免疫组化法检测PTCL患者肿瘤组织中PD-1、PD-L1蛋白的表达,并分析其表达与患者临床分期、疗效及预后之间的关系。结果 PTCL患者肿瘤组织中PD-1蛋白的表达阳性率为35%,PD-L1蛋白的阳性率为70%,炎性淋巴结组织中未见PD-1、PD-L1表达,PD-1、PD-L1蛋白的表达与患者临床分期正相关,PD-1蛋白的表达与疗效负相关,PD-1与PD-L1蛋白双阳性的PTCL患者生存期明显缩短。结论PTCL患者淋巴瘤组织中PD-1和PD-L1蛋白表达阳性率高于炎性淋巴结组织,是预后不良的指标。 Objective To investigate the protein expression of programmed cell death-1 (PD-1) and programmed death ligand 1 (PD-L1) in the tissues of peripheral T-cell lymphoma (PTCL), and to analyze the relationship between its expression, chemotherapeu- tic effect and prognosis. Methods The expressions of PD-1 and PD-L1 protein in tumor tissue of PTCL were detected by immunohis toehemistry. The correlation between the protein expressions, clinical stages and prognosis was evaluated. Results In tumor tissues of PTCL patients, the expression rate of PD-1 protein was 35%, while the expression rate of PD-L1 was 70%. In the normal inflamma- tory lymph nodes, the expression of PD-L1 and PD-1 were not found. The expressions of PD-1 and PD-L1 were positively correlated with clinical stages. The expression of PD-1 was negatively correlated with curative effect. Survival rate was signi/icantly lower in the patients with PD-L1 and PD-1 co-expression. Conclusion The expression rates of PD-1 and PD-L1 protein in lymphoma tissues of PTCL patients were higher than in normal inflammatory lymph nodes, and they may be the potential indicators of poor prognosis.
出处 《肿瘤药学》 CAS 2016年第1期44-48,共5页 Anti-Tumor Pharmacy
基金 广东省医学科学技术研究基金项目(B2015039)
关键词 外周T细胞淋巴瘤(PTCL) 程序性细胞死亡受体1(PD-1) 程序性细胞死亡受体1配体(PDL-1) 预后 Peripheral T cell lymphoma (PTCL) PD-1 PD-L1 Prognosis
  • 相关文献

参考文献5

二级参考文献61

  • 1张晶,谢幸,叶大风.黏附分子与肿瘤免疫逃逸[J].实用肿瘤杂志,2004,19(5):449-452. 被引量:18
  • 2Carter L,Fouser L A,Jussif J,et al.PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2[J].Eur J Immunol,2002,32(3):634-643.
  • 3Latchman Y,Wood C R,Chernova T,et al.PD-L2 is a second ligand for PD-1 and inhibits T cell activation[J].Nat Immunol,2001,2(3):261-268.
  • 4Dong H,Zhu G,Tamada K,et al.B7-H1,a third member of the B7 family,co-stimulates T-cell proliferation and interleukin-10 secretion[J].Nat Med,1999,5(12):1365-1369.
  • 5Al-Shibli K,Al-Saad S,Donnem T,et al.The prognostic value of intraepithelial and stromal innate immune system cells in non-small cell lung carcinoma[J].Histopathology,2009,55(3):301-312.
  • 6Haspot F,Fehr T,Gibbons C,et al.Peripheral deletional tolerance of alloreactive CD8 but not CD4 T cells is dependent on the PD-1/PD-L1 pathway[J].Blood,2008,112(5):2149-2155.
  • 7Konishi J,Yamazaki K,Azuma M,et al.B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression[J].Clin Cancer Res,2004,10(15):5094-5100.
  • 8Wu K,Kryczek I,Chen L,et al.Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions[J].Cancer Res,2009,69(20):8067-8075.
  • 9乔友林.中国妇女人乳头瘤病毒感染和子宫颈癌的流行病学研究现状及其疫苗预防前景[J].中华流行病学杂志,2007,28(10):937-940. 被引量:92
  • 10Dong HD,Zhu GF,Tamada K,et al. B7-H1,a third member ofthe B7 family,co-stimulates T-cell proliferation and interieukin-lOsecretion. Nat Med,1999; 5(12) :1365 -1369.

共引文献123

同被引文献31

引证文献7

二级引证文献62

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部